This call for proposals is dedicated to the design and construction of low-cost, resilient, energy efficient, and safe housing for First Nations communities, an area of immediate and high priority for IC-IMPACTS.

Your proposal must reflect the principles of Equity, Diversity, and Inclusion in order to increase equity and enhance research excellence. IC-IMPACTS is committed to the principles of Equity, Diversity, and Inclusion, adopted from NSERC’s Statement on Equity, Diversity, and Excellence in Natural Sciences and Engineering Research.

Partnership Engage Grants are expected to respond to the objectives of the Insight program and the Connection program. Please note that Partnership Engage Grants cannot respond exclusively to the objectives of the Connection program.

They provide short-term and timely support for partnered research activities that will inform decision-making at a single partner organization from the public, private or not-for-profit sector. The small-scale, stakeholder-driven partnerships supported through the Partnership Engage Grants are meant to respond to immediate needs and time constraints facing organizations in non-academic sectors. In addressing an organization-specific need, challenge and/or opportunity, these partnerships let non-academic organizations and postsecondary researchers access each other’s unique knowledge, expertise and capabilities on topics of mutual interest.

SSHRC welcomes applications involving Indigenous research, as well as those involving research-creation.

The objective of the Idea to Innovation (I2I) Grants is to accelerate the pre-competitive development of promising technology originating from the university and college sector and promote its transfer to a new or established Canadian company. The I2I Grants provide funding to college and university faculty members to support research and development projects with recognized technology transfer potential. This is achieved through defined phases by providing crucial assistance in the early stages of technology validation and market connection.

The FY19 Defense Appropriation provides $16 million (M) to the Department of Defense Parkinson’ Research Program (PRP) to support research to understand, prevent, diagnose, and treat Parkinson’s disease.  Applications to the FY19 PRP are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA).  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 PRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

IMPORTANT:  The PRP seeks to focus applications and direct funding by providing Focus Areas to address the critical needs in Parkinson’s disease research. 

https://cdmrp.army.mil/funding/prp

Investigator-Initiated Research Award – Letter of Intent due July 9, 2019

Assistant Professor Level of above (or equivalent)

• ·        Supports highly rigorous, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research and/or patient care.
• ·        Potential impact of research may be near term or long term, but it must be significant and go beyond an incremental advancement.
• ·        Must address at least one of the Fy19 PRP Focus Areas.
• ·        Preliminary data to support feasibility are encouraged. 
• ·        Submission of a Letter of Intent is require prior to full application submission.
• ·        Clinical trials not allowed

Partnering PI Option:

• ·        Provides a higher level of funding to support synergistic partnerships between two or three independent investigators collaborating on a single application.
• ·        PIs are expected to demonstrate within the application the synergistic components that will significantly advance the project, such that the research outcomes could not otherwise be accomplished through the independent efforts of a single PI.
  • ·        The proposed partnership should result in a level of productivity that is greater than that achievable by each PI independently. 

Individual PI:

• ·       Maximum funding of $1.5 million (M) for total costs (includes direct and indirect costs)
• ·       Maximum period of performance 3 years

Partnering PI Option:

• ·       Maximum funding of $2.4M for total costs (includes direct and indirect costs)
• ·       Maximum period of performance 3 years

Early Investigator Research Award – Letter of Intent due July 9, 2019

Investigator must be a postdoctoral or clinical fellow, instructor, or assistant professor within 10 years of advanced degree or residency training (or equivalent)

• ·         Supports early-career investigators exploring innovative, high-impact ideas or new technologies applicable to Parkinson’s disease research and/or patient care.
• ·         PIs must have a designated mentor who is an experienced Parkinson’s disease researcher.
• ·         Must address at least one of the FY19 PRP Focus Areas.
• ·         Preliminary data not required.
• ·         Submission of a Letter of Intent is required prior to full application submission.
• ·         Clinical trials not allowed
• ·         Maximum funding of $360,000 for total costs (includes direct and indirect costs)
• ·         Maximum period of performance 2 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507

help@eBrap.org

The FY19 Defense Appropriation provides $14 million (M) to the Department of Defense Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 LCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

Applications submitted to the FY19 LCRP must address at least one of the nine Areas of Emphasis listed below:

• Identify innovative strategies for the screening and early detection of lung cancer.
• Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.
• Identify innovative strategies for prevention of the occurrence of lung cancer.
• Identify innovative strategies for the treatment of lung cancer.
• Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.
• Develop or optimize predictive markers to assist with therapeutic decision-making.
• Understand mechanisms of resistance to treatment (primary and secondary).
• Understand contributors to lung cancer development other than tobacco.
• Identify innovative strategies for lung cancer care delivery (clinical management/ surveillance/symptom management).

Military Relevance:  The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families.  Military relevance will be considered in determining relevance to the mission of the DHP and FY19 LCRP during programmatic review.  Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate military relevance:

• Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research
• Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators
• Involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area
• Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population
• Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco

https://cdmrp.army.mil/funding/lcrp

Career Development Award – Letter of Intent due August 1, 2019

• ·         Principal Investigator:  Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment.
• ·         Must not have received a Career Development Award previously from any program within the Congressionally Directed Medical Research Programs.
• ·         Must not have received more than $300,000 in total direct costs for previously or concurrent lung cancer research as a PI of one or more federally or privately funded, non-mentored, peer-reviewed grants.
• ·         Mentor:
• ·         At or above the level of Associate Professor (or equivalent)
• ·         Must have a proven publication and funding record in lung cancer research.
• ·         Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher.
• ·         Clinical trials not allowed.
• ·         Preliminary data not required.
• ·         Relevance to Military Health strongly encouraged.
• ·         Maximum funding of $250,000 in direct costs (plus indirect costs).
• ·         Period of performance should not exceed 2 years.

Idea Development Award –Preproposal due May 15, 2019

• ·         Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent); or
• ·         New Investigators:  Investigators must meet the following criteria at the application submission deadline date:
• ·         Have not previously received a LCRP Idea Development Award or LCRP Early Investigator Synergistic Idea Award
• ·         Be within 10 years of first faculty appointment (or equivalent)
• ·         Relevance Military Health strongly encouraged.
• ·         Maximum funding of $350,000 in direct costs (plus indirect costs).
• ·         Period of performance should not exceed 2 years.

• Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.
• Emphasis on innovation and impact.
• New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers.
• Clinical trials not allowed.
• Preliminary data required, but may be from outside of lung cancer.

Investigator-Initiated Translational Research Award – Preproposal due May 15, 2019

• ·         Independent investigators at or above the level of Assistant Professor (or equivalent)
• ·         Relevance to Military Health strongly encouraged.
• ·         Maximum funding of $400,000 in direct costs (plus indirect costs).
• ·         Period of performance should not exceed 2 years.

• Supports translational research that will develop promising ideas in lung cancer into clinical applications.  Translational research may be defined as an integration of basic science and clinical observations.
• Intended to fund a broad range of translational studies.
• Clinical trials not allowed.
• Preliminary data required.

Translational Research Partnership Award – Preproposal due May 15, 2019

• ·         Investigators at or above the level of Assistant Professor (or equivalent)
• ·         One partner is strongly encouraged to be from Department of Defense military treatment facility or laboratory, or Veterans Affairs medical center.
• ·         Clinical trials are allowed.
• ·         Relevance to Military Health strongly encouraged.

• Supports partnerships between clinicians and research scientists that accelerate ideas in lung cancer into clinical applications.

• Nontraditional Partnerships are encouraged.
• Preliminary data required.

• Maximum combined funding of $900,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

CIHR and FRQ have decided to support Canadian investigators on a large-scale, interdisciplinary, international brain research initiative. Understanding how behavior emerges from the dynamic patterns of electrical and chemical activity of brain circuits is universally recognized as one of the great, unsolved mysteries of science. Advances in recent decades have elucidated how individual elements of the nervous system and brain relate to specific behaviors and cognitive processes. However, there remains much to discover to attain a comprehensive understanding of how the healthy brain functions, specifically, the general principles underlying how cognition and behavior relate to the brain’s structural organization and dynamic activities, how the brain interacts with its environment, and how brains maintain their functionality over time.

As part of the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative in the United States, the US National Science Foundation (NSF) has developed the Next Generation Networks for Neuroscience (NeuroNex). The objective of the NeuroNex program is the establishment of distributed, international research networks that build on existing global investments in neurotechnologies to address overarching questions in neuroscience. The creation of such global research networks of excellence will foster international cooperation by seeding close interactions between a wide array of organizations across the world, as well as creating links and articulating alliances between multiple recently launched international brain projects. Canadian researchers are well placed to provide a leadership role within NeuroNex networks.

The goal of the NeuroNex Technology-enabled, Team-based Neuroscience solicitation is to support collaborative networks comprised of international teams of disciplinarily-diverse researchers working on a common foundational question in neuroscience. Each network will be organized around a central theme identified by the participants. Individual networks will be composed of 2 to 4 interdisciplinary research groups (IRGs), each consisting of about 3 to 6 investigators. Each IRG will have a defined intellectual role that fits within the overall research goal of the network. It is envisaged that the composition of each IRG may cut across organizations and countries, as appropriate. Through this funding opportunity, CIHR and FRQ will support Canadian investigators on NeuroNex IRGs.

Research Areas

A Network must be composed of international teams (IRGs) that include disciplinarily-diverse experimentalists and theorists working to obtain mechanistic insights into foundational questions in neuroscience. These networks must incorporate:

• Strong integration across levels of study within an organism
• Comparative analysis of neural underpinnings of behavior in naturalistic settings
• Predictive theory and modeling to guide research and uncover general principles
• Global partnerships

The Indigenous Health Nursing Chair initiative is expected to:

• Support research and development of knowledge and best and wise practices in the area of Indigenous health nursing
• Investigate structural factors, including gender, that support and impede Indigenous health nursing and Indigenous health
• Explore, describe and/or explain Indigenous research paradigms and their theoretical and methodological implications for Indigenous health nursing standards
• Advance the understanding and conceptualization of Indigenous health nursing and its role in the nursing profession
• Examine the recruitment and retention of people into the nursing discipline (i.e., practice, education, research and administration) and nurses into the specialty of Indigenous health nursing
• Create opportunities and the will for nurses and trainees to engage in Indigenous health nursing leadership
• Provide mentorship and training for students

As stated in CIHR's Strategic Plan, Health Research Roadmap II: Capturing Innovation to Produce Better Health and Health Care for Canadians, CIHR wants to seize the momentum and contribute to innovative, evidence-informed eHealth solutions that will improve patient experiences, health outcomes and the sustainability of the health care system, as well as engage with the international community. As a way of expanding the opportunities for funding and engagement in international markets for ideas and industries, this program enables CIHR to leverage the value of its funding investments by participating in transnational joint calls in eHealth research.  

This funding opportunity lies within the scope of the International component of CIHR's eHealth Innovations Initiative (eHII). The Active and Assisted Living Programme (AAL) provides Canada with an established and successful mechanism to foster international collaborations and offers the opportunity to engage diverse communities in generating transformative eHealth solutions.

The AAL Programme is a common funding activity of member states of the AAL Association, with the financial support of the European Commission, based on article 185 of the Treaty on the Functioning of the European Union. The AAL Programme calls are complementary to the Horizon 2020 calls related to Active and Healthy Ageing under Societal Challenge 1 (SC1), as well as to the Horizon 2020 2018-2020 Work Programme on Information and Communication Technologies [ PDF (1190 KB) - external link ].

The aim of the AAL Programme is to provide innovative Information and Communication Technologies (ICT) based solutions including products, systems or services. These solutions aim to enhance older adults' quality of life, to improve the long-term sustainability of the health and long-term care systems and to strengthen the industrial base in Europe and internationally. The main goal is to improve the autonomy, participation in social life, skills, and employability of older adults.

The challenge-led Call for Proposals AAL 2019: Sustainable Smart Solutions for Ageing Well is part of the AAL Programme that was approved in May 2014 by the European Parliament and the Council of the European Union.

The AAL Call 2019 is open to collaborative projects developing ICT-based solutions targeting any application area(s) within the AAL domain, with a focus on specified markets (Consult AAL website for more information on different markets). The solutions need to be embedded into the strategies of the participating end-user organizations, service providers and business partners. The wishes and aspirations of older adults in combination with the demands from the other stakeholders involved – e.g. providers and payers - will have a critical role in shaping useful and attractive AAL solutions with a high market potential.

Although the AAL Call 2019 is supporting two types of projects, CIHR will only be funding Collaborative Projects:

• Collaborative projects are multi-annual projects that are expected to be user-driven through co-creation and address a specified challenge. Furthermore, the route to market needs to be clearly described and aligned with the business strategies of the partners responsible for commercialisation. Collaborative projects (carried out by consortia composed of at least 3 organisations from 3 different countries including an end user organisation and a business partner) are the main funding tools for this call. This type of project has a duration of 18 to 36 months with maximum funding of €2.500.000.

For more information, and the full call text please consult the Active and Assisted Living website.

Concussion is recognized as a serious public health epidemic, particularly in children, where rates have doubled over the last decade, with an estimated 750,000 pediatric acute concussion visits to emergency departments (EDs) occurring annually in the United States alone. While many children experience symptom resolution within 2 weeks, approximately 33% experience ongoing cognitive, somatic, psychological, behavioural symptoms, or a combination of these symptoms, known as “Persistent Post-Concussive Symptoms, or PPCS”.

In 2012 Canada (through CIHR) became one of three founding countries in the “International Initiative for TBI Research (InTBIR), along with the European Union (EU Health Directorate) and the United States (NIH-NINDS). As part of the executive leadership in InTBIR, The Institute of Neurosciences, Mental Health and Addiction (CIHR-INMHA) and partners launched $10M worth of funding opportunities including five team grants in pediatric concussion. In March 2016 one of these teams, led by Roger Zemek, published the first clinical prediction tool to identify children at risk of PPCS) Given the leadership role of Canadian researchers in concussion, CIHR-INMHA was approached by its InTBIR partner NIH-NINDS to participate on this new bilateral funding opportunity.

This funding opportunity represents the next step of the continuing Canadian and American investments into pediatric concussion research, care, and knowledge exchange.

For more information, please consult the NIH call. (Updated: 2019-03-22)

The FY19 Defense Appropriation provides $90 million (M) to the U.S. Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Congressionally Directed Topic Areas:  To be considered for funding, applications for the FY19 PRCRP must address at least one of the Topic Areas as directed by Congress.  Research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, melanoma, or ovarian cancer will not be accepted.

The FY19 PRCRP Topic Areas are:

*The definition of adolescents and young adults is derived from the National Cancer Institute (https://www.cancer.gov/types/aya) and can be considered to be people between 15 and 39 years of age.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s). Research should be targeted toward children (ages 0-14 years), adolescents (ages 15-24 years), and/or young adults (ages 25-39 years).

^†As derived from the National Cancer Institute Dictionary of Cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms).  Immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

^ǂRare cancer is defined by the National Cancer Institute as a cancer that occurs in fewer than 15 out of 100,000 people each year.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

The FY19 PRCRP Military Relevance Focus Areas are listed below:

It is central to the vision and mission of the PRCRP that applications address how the proposed research is related to military health and mission readiness of both deployed and non-deployed personnel, their dependents, retirees, and Veterans. The FY19 PRCRP requires all applications to respond to at least one of Military Relevance Focus Areas listed below:

• Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, environmental carcinogens, and stress)
• Gaps in cancer prevention, early detection/diagnosis, prognosis, treatment, and/or survivorship that may impact mission readiness and the health and well-being of military members, Veterans, their beneficiaries, and the general public

https://cdmrp.army.mil/funding/prcrp

Career Development Award – Letter of Intent due August 21, 2019

Principal Investigator (PI): Independent investigator within 10 years of completing terminal degree (excluding time spent in medical residency, clinical training, or on family medical leave) by the time of the application submission; time spent as a postdoctoral fellow is not excluded.

Postdoctoral fellows are not eligible.

Career Guide: Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in cancer research. 

The PI and the Career Guide do not need to be located at the same organization.\

• ·         Letter of Intent is required.  An invitation to submit a full application is not required.
• ·         Supports independent, early-career investigators to conduct impactful research, together with the guidance of an experienced cancer researcher.
• ·         Must address at least one of the FY19 PRCRP Topic Areas.
• ·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.
• ·         Preliminary data are not required.
• ·         Clinical trials are not allowed.
• ·       Maximum funding for the entire period of performance is $360,000 for direct costs (plus indirect costs).
• ·       Maximum period of performance is 3 years.

Horizon Award – Letter of Intent due August 21, 2019

Principal Investigator (PI):

Predoctoral candidate within 2 years of completion of required coursework/laboratory rotations, successfully passed qualifying examinations, and is working in his/her Mentor’s laboratory application submission deadline.

Or

Postdoctoral fellow within 3 years of completion of terminal degree and is working in his/her Mentor’s laboratory at application submission deadline.

Mentor: Investigators at or above the level of Assistant Professor (or equivalent); must have a proven publication and funding record in cancer research. 

PI and Mentor must be at the same organization.

• ·         Letter of Intent is required.  An invitation to submit a full application is not required.
• ·         Supports junior-level scientists in conducting impactful research with the mentorship of an experienced cancer researcher (i.e., Mentor).
• ·         Must address at least one of the FY19 PRCRP Topic Areas.
• ·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.
• ·         Preliminary data are not required.
• ·         Clinical trials are not allowed.
• ·       Maximum funding for the entire period of performance is $150,000 for direct costs (plus indirect costs).
• ·       Maximum period of performance is 2 years.

Idea Award with Special Focus –Preproposal due May 22, 2019

Independent investigator with a faculty-level appointment (or equivalent).

• ·         Preproposal is required; application submission is by invitation only.
• ·         Supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research relevant to Service members, Veterans, military beneficiaries, and the American public.
• ·         Emphasis on innovation and military relevance/impact.
• ·         Must address at least one of the FY19 PRCRP Topic Areas.
• ·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.
• ·         Inclusion of preliminary data are not required.
• ·         Clinical trials are not allowed.
• ·       Maximum funding for the entire period of performance is $400,000 for direct costs (plus indirect costs).
• ·       Maximum period of performance is 2 years.

Impact Award – Preproposal due May 22, 2019

Independent investigators at or above the level of Assistant Professor (or equivalent).

Only one pre-application per PI is allowed.

• ·         Preproposal is required; application submission is by invitation only.
• ·         Supports hypothesis-driven, high impact research.
• ·         Encourages applications that support the ideas that specifically focus on critical scientific and clinical cancer issues.
• ·         Emphasis on impact, transformation, and continuity of research.
• ·         Must address at least one of the FY19 PRCRP Topic Areas.
• ·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.
• ·         Preliminary data are required.
• ·         Clinical Trials are allowed.
• ·       Maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs).
• ·       Maximum period of performance is 3 years.

Translational Team Science Award – Preproposal due May 22, 2019

At least two and up to three PIs must partner in one overarching correlative or translational research study in at least one of the required FY19 PRCRP Topic Areas.

The PIs must be at or above the level of Assistant Professor or equivalent.

• ·         Preproposal is required; application submission is by invitation only.
• ·         Emphasizes multi-PI, multidisciplinary collaborations.
• ·         Supports hypothesis-driven translational studies that are associated with an ongoing or completed clinical trial and are focused on research for the next-phase clinical research.
• ·         Must address at least one of the FY19 PRCRP Topic Areas.
• ·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.
• ·         Encourages research in interventions to improve the quality of life, cancer prevention, and metastasis.
• ·         Preliminary data are required.
• ·         Clinical Trials are allowed.
• ·       Maximum funding for the entire period of performance is $1,500,000 for direct costs (plus indirect costs).
• ·       Maximum period of performance is 4 years.

A pre-application (letter of intent or pre-proposal) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507 
help@eBrap.org